Nitisinone: Phase I data

An open-label Phase I trial in 14 patients showed that SYN-118 was well tolerated and significantly improved motor function on the UPDRS scale from baseline to day 28 during "off" times in which patients experienced symptoms of their PD (p=0.003). SYN-118 non-significantly improved motor function from baseline to day 28 during "on" times in which patients were symptom free. Data were presented at the World Parkinson Congress in Glasgow. ...